Targeted agents for sarcoma: Is individualized therapy possible in such a diverse tumor type?

Seminars in Oncology

Volumn 38, Issue SUPPL. 3, 2011, Pages

  Riedel, Richard F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; AT 13387; BEVACIZUMAB; CEDIRANIB; CIXUTUMUMAB; CRIZOTINIB; CYCLOPHOSPHAMIDE; DACARBAZINE; DASATINIB; DOCETAXEL; EVEROLIMUS; GANITUMAB; GEFITINIB; GEMCITABINE; IMATINIB; MASITINIB; NILOTINIB; PACLITAXEL; PAZOPANIB; R 1507; REOLYSIN; RETASPIMYCIN; RIDAFOROLIMUS; RO 5045337; ROMIDEPSIN; SORAFENIB; SUNITINIB; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ADJUVANT THERAPY; ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; ARTICLE; BONE MARROW SUPPRESSION; CANCER THERAPY; CLEAR CELL SARCOMA; DERMATOFIBROSARCOMA PROTUBERANS; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EWING SARCOMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEMANGIOPERICYTOMA; HISTIOCYTOMA; HUMAN; HYPERTENSION; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT NEOPLASTIC DISEASE; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL GRANULOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; SYNOVIAL SARCOMA; SYSTEMIC THERAPY;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; GENES, NEOPLASM; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS;

EID: 80355149465     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.09.003     Document Type: Article

References (91)

1. R. Wesolowski, and G.T. Budd Use of chemotherapy for patients with bone and soft-tissue sarcomas Cleve Clin J Med 77 Suppl 1 2010 S23 S26
2. D. Mahalingam, A. Mita, and K. Sankhala Targeting sarcomas: novel biological agents and future perspectives Curr Drug Targets 10 2009 937 949
3. K.U. Patel, S.S. Szabo, and V.S. Hernandez Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays Hum Pathol 39 2008 184 193
4. D. Kérob, R. Porcher, and O. Vérola Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients Clin Cancer Res 16 2010 3288 3295
5. G.A. McArthur, G.D. Demetri, and A. van Oosterom Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225 J Clin Oncol 23 2005 866 873 (Pubitemid 46224187)
6. D.G. Thomas, T.J. Giordano, and D. Sanders Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma Cancer 103 2005 830 838 (Pubitemid 40216413)
7. S. Hirota, K. Isozaki, and Y. Moriyama Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 1998 577 580 (Pubitemid 28067289)
8. J. Barretina, B.S. Taylor, and S. Banerji Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy Nat Genet 42 2010 715 721
9. L. Gibault, G. Pérot, and F. Chibon New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics J Pathol 223 2011 64 71
10. T. Peng, P. Zhang, and J. Liu An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors Lab Invest 91 2010 392 403
11. E.E. Pakos, A.C. Goussia, P.G. Tsekeris, D.J. Papachristou, D. Stefanou, and N.J. Agnantis Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas Anticancer Res 25 2005 3591 3596 (Pubitemid 41105246)
12. M.S. Park, V. Ravi, and D.M. Araujo Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor Curr Opin Oncol 22 2010 351 355
13. J.-Y. Blay A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST Cancer Treat Rev 37 2010 373 384
14. G.D. Demetri, M. von Mehren, and C.D. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480 (Pubitemid 34879334)
15. C.D. Blanke, G.D. Demetri, and M. von Mehren Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 2008 620 625 (Pubitemid 351264357)
16. M. von Mehren, M.C. Heinrich, H. Joensuu, C.D. Blanke, E. Wehrle, and G.D. Demetri Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST) J Clin Oncol 29 Suppl 2011 abstract 10016
17. C.D. Blanke, C. Rankin, and G.D. Demetri Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 2008 626 632 (Pubitemid 351264358)
18. J. Verweij, P.G. Casali, and J. Zalcberg Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial Lancet 364 2004 11374
19. R.P. Dematteo, K.V. Ballman, and C.R. Antonescu Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 2009 1097 1104
20. G.D. Demetri, M. von Mehren, and C.R. Antonescu NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors J Natl Compr Canc Netw 8 Suppl 2 2010 S1 S41
21. M.C. Heinrich, K. Owzar, and C.L. Corless Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group J Clin Oncol 26 2008 5360 5367
22. R.P. DeMatteo, K.V. Ballman, and C.R. Antonescu Placebo-controlled randomized trial of adjuvant imatinib mesylate following the resection of localized, primary gastrointestinal stromal tumor (GIST) Lancet 373 2009 1097 1104
23. H. Joensuu, M. Eriksson, and J. Hatrmann Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO) J Clin Oncol 29 Suppl 2011 abstract LBA1
24. National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidences in Oncology (NCCN Guidelines): Soft Tissue Sarcoma Version 1.2011 NCCN.org Accessed March 24, 2011
25. P.G. Casali, and J.Y. Blay Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl 5 2010 v98 v102
26. G.D. Demetri, A.T. van Oosterom, and C.R. Garrett Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338 (Pubitemid 44528723)
27. G.D. Demetri, X. Huang, and C.R. Garrett Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure J Clin Oncol 26 Suppl 2008 abstract 10524
28. M.C. Heinrich, R.G. Maki, and C.L. Corless Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumors J Clin Oncol 26 2008 5352 5359
29. H.L. Kindler, N.P. Campbell, and K. Wroblewski Sorafenib in patients with imatinib and sunitinib-resistant gastrointestinal stromal tumors (GIST): final results of a University of Chicago phase II consortium trial J Clin Oncol 29 Suppl 2011 abstract 4
30. P. Reichardt, M. Montemurro, and H. Gelderblom Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: a retrospective analysis J Clin Oncol 27 Suppl 2009 abstract 10564
31. M. Montemurro, P. Schoffski, and P. Reichardt Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib Eur J Cancer 45 2009 2293 2297
32. J.C. Trent, K. Wathen, and M. von Mehren Sarcoma Alliance for Research through Collaboration A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST) J Clin Oncol 29 Suppl 2011 abstract 10006
33. H. Choi, C. Charnsangavej, and S.C. Faria Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 2007 1753 1759 (Pubitemid 46797957)
34. J. Blay, A. Le Cesne, and N. Bin Bui Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-year follow-up of the French Sarcoma Group phase II trial J Clin Oncol 29 Suppl 2011 abstract 85
35. US National Institutes of Health http://ClinicalTrials.gov Accessed August 12, 2011
36. S. George, P. Merriam, and R.G. Maki Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas J Clin Oncol 27 2009 3154 3160
37. S. Stacchiotti, T. Negri, and N. Zaffaroni Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect Ann Oncol 22 2011 1682 1690
38. R.G. Maki, D.R. D'Adamo, and M.L. Keohan Phase II study of sorafenib in patients with metastatic or recurrent sarcomas J Clin Oncol 27 2009 3133 3140
39. A. Bertuzzi, E.M. Stroppa, and S. Secondino Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy J Clin Oncol 28 15S 2010 abstract 10025
40. S. Sleijfer, I. Ray-Coquard, and Z. Papai Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043) J Clin Oncol 27 2009 3126 3132
41. W.T. Van der Graaf, J.Y. Blay, and S.P. Chawla PALETTE: a randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapyan EORTC STBSG Global Network Study (EORTC 62072) J Clin Oncol 29 Suppl 2011 abstract LBA10002
42. K. Gardner, I. Judson, and M. Leahy Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma J Clin Oncol 27 15S 2009 abstract 10523
43. M. Agulnik, S.H. Okuno, and M. Von Mehren An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma J Clin Oncol 27 15S 2009 abstract 10522
44. M.S. Park, S.R. Patel, and J.A. Ludwig Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor J Clin Oncol 26 Suppl 2008 abstract 10512
45. S.P. Chawla, J.Y. Blay, and I.L. Ray-Coquard Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT) J Clin Oncol 29 Suppl 2011 abstract 10005
46. A.W. Tolcher, J. Sarantopoulos, and A. Patnaik Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 J Clin Oncol 27 2009 5800 5807
47. A.S. Pappo, S. Patel, and J.J. Crowley Sarcoma Alliance for Research through Collaboration Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): results of a phase II SARC study J Clin Oncol 28 15S 2010 abstract 10000
48. S. Patel, A.S. Pappo, and J.J. Crowley A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas J Clin Oncol 27 15S 2009 abstract 10503
49. I. Ray-Coquard, A. Le Cesne, and J.S. Whelan A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens Oncologist 13 2008 467 473 (Pubitemid 351679928)
50. J.E. Butrynski, D.R. D'Adamo, and J.L. Hornick Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor N Engl J Med 363 2010 1727 1733
51. J. Goldberg, G.D. Demetri, and E. Choy Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors J Clin Oncol 27 15S 2009 abstract 10502
52. T. Ito, M. Ouchida, and Y. Morimoto Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo Cancer Lett 224 2005 311 319 (Pubitemid 40725851)
53. W. Kwan, J. Terry, S. Liu, M. Knowling, and T.O. Nielsen Effect of depsipeptide (NSC 630176), a histone deacetylase inhibitor, on human synovial sarcoma in vitro J Clin Oncol 23 16S 2005 abstract 9039
54. A.J. Wagner, J.A. Morgan, R. Chugh, L.S. Rosen, and S. George Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial J Clin Oncol 26 Suppl 2008 abstract 10503
55. G.D. Demetri, A. Le Cesne, M. Von Mehren, B. Chmielowski, and S. Bauer Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies Presented at: Gastrointestinal Cancers Symposium January 22-24, 2010 Orlando, FL. Abstract 64
56. US National Institutes of Health A study to investigate the safety and efficacy of AT13387, alone or in combination with imatinib, in patients with GIST (NCT01294202) http://.clinicaltrials.gov/ct2/show/NCT01294202 Accessed July 11, 2011
57. A. Mita, K. Sankhala, J. Sarantopoulos, J. Carmona, and S.H. Okuno A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung J Clin Oncol 27 15S 2009 abstract 10524
58. S.T. Mahmood, S. Agresta, and C. Vigil Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma Int J Cancer 2010 Dec 10 [Epub ahead of print]
59. E. Fox, R. Aplenc, and R. Bagatell A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors J Clin Oncol 28 2010 5174 5181
60. S. Kummar, A. Strassberger, and A. Monks An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS) J Clin Oncol 29 Suppl 2011 abstract 10001
61. C.K. Fuller, J.A. Charlson, S.K. Dankle, and T.J. Russell Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy J Am Acad Dermatol 63 2010 e83 e84
62. A. Rosen, S. Thimon, D. Ternant, M.C. Machet, G. Paintaud, and L. Machet Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face Br J Dermatol 163 2010 225 227
63. C.F. Verschraegen, H. Arias-Pulido, and S.J. Lee Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen Ann Oncol 2011 Jul 11 [Epub ahead of print]
64. D.R. D'Adamo, S.E. Anderson, and K. Albritton Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas J Clin Oncol 23 2005 7135 7142
65. P. Leavey, J.L. Glade Bender, and L. Mascarenhas Feasibility of bevacizumab (NSC 704865, BB-IND# 7921) combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma (EWS): a Children's Oncology Group (COG) study J Clin Oncol 28 15S 2010 abstract 9552
66. J.Y. Blay Updating progress in sarcoma therapy with mTOR inhibitors Ann Oncol 22 2011 280 287
67. S. Vemulapalli, A. Mita, Y. Alvarado, K. Sankhala, and M. Mita The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas Target Oncol 6 2011 29 39
68. X. Wan, and L.J. Helman The biology behind mTOR inhibition in sarcoma Oncologist 12 2007 1007 1018 (Pubitemid 47359144)
69. M.M. Mita, A.C. Mita, and Q.S. Chu Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies J Clin Oncol 26 2008 361 367 (Pubitemid 351171685)
70. S. Chawla, A.W. Tolcher, and A.P. Staddon Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial J Clin Oncol 25 18S 2007 abstract 10076
71. S. Okuno, H. Bailey, and M.R. Mahoney A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas Cancer 117 2011 3468 3475
72. A. Italiano, M. Kind, E. Stoeckle, N. Jones, J.M. Coindre, and B. Bui Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway Anticancer Drugs 22 2011 463 467
73. M.A. Pantaleo, A. Astolfi, and M. Di Battista Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target Int J Cancer 125 2009 2991 2994
74. A. Prieur, F. Tirode, P. Cohen, and O. Delattre EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3 Mol Cell Biol 24 2004 7275 7283 (Pubitemid 39014452)
75. B. Rikhof, S. de Jong, A.J. Suurmeijer, C. Meijer, and W.T. van der Graaf The insulin-like growth factor system and sarcomas J Pathol 217 2009 469 482
76. O. Sato, T. Wada, and A. Kawai Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases Cancer 103 2005 1881 1890 (Pubitemid 40563261)
77. K.H. Albritton, C. Rankin, and C.M. Coffin Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST) J Clin Oncol 24 18S 2006 abstract 9518
78. K. Scotlandi, M.C. Manara, and C.M. Hattinger Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma Eur J Cancer 41 2005 1349 1361 (Pubitemid 40813013)
79. R.H. Palmer, E. Vernersson, C. Grabbe, and B. Hallberg Anaplastic lymphoma kinase: Signalling in development and disease Biochem J 420 2009 345 361
80. C.M. Coffin, A. Patel, S. Perkins, K.S. Elenitoba-Johnson, E. Perlman, and C.A. Griffen ACK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor Mod Pathol 14 2001 569 576 (Pubitemid 32554081)
81. C.A. Griffen, A.L. Hawkins, C. Dvorak, C. Henkle, T. Ellingham, and E.J. Perlman Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors Cancer Res 59 1999 2776 2780 (Pubitemid 29283106)
82. R. Ferracini, M.F. Di Renzo, and K. Scotlandi The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit Oncogene 10 1995 739 749
83. I.J. Davis, A.W. McFadden, and Y. Zhang Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma Cancer Res 70 2010 639 645
84. M. Tsuda, I.J. Davis, and P. Argani TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition Cancer Res 67 2007 919 929
85. C. Birchmeier, and E. Gherardi Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase Trends Cell Biol 8 1998 404 410 (Pubitemid 28458706)
86. A. Ganesan, L. Nolan, S.J. Crabb, and G. Packham Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery Curr Cancer Drug Targets 9 2009 963 981
87. L. Su, H. Cheng, A.V. Sampaio, T.O. Nielsen, and T.M. Underhill EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor Oncogene 29 2010 4352 4361
88. T. Mhlenberg, Y. Zhang, and A.J. Wagner Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors Cancer Res 69 2009 6941 6950
89. L. Guillou, and A. Aurias Soft tissue sarcomas with complex genomic profiles Virchows Arch 456 2010 201 217
90. K.I. Pishas, F. Al-Ejeh, and I. Zinonos Nutlin-3a is a potential therapeutic for ewing sarcoma Clin Cancer Res 17 2011 494 504
91. Z. Helias-Rodzewicz, F. Pedeutour, J.M. Coindre, P. Terrier, and A. Aurias Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma Genes Chromosomes Cancer 48 2009 943 952